{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-ind-safety-reporting-specifics-under-21-cfr-312-32-us-timelines”
},
“headline”: “SOP for IND Safety Reporting Specifics under 21 CFR 312.32 (US Timelines)”,
“description”: “This SOP defines procedures for IND safety reporting under 21 CFR 312.32, covering expedited reporting of SAEs and SUSARs, timelines for submission, sponsor and investigator responsibilities, and inspection readiness in the United States.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for IND Safety Reporting Specifics under 21 CFR 312.32 (US Timelines)

Purpose

The purpose of this SOP is to describe specific requirements for safety reporting under 21 CFR 312.32 for IND-regulated clinical trials in the United States. It ensures timely identification, evaluation, and reporting of serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) to the FDA in compliance with regulatory timelines.

Scope

This SOP applies to sponsors, investigators, CROs, pharmacovigilance teams, and regulatory affairs personnel responsible for safety monitoring and reporting in U.S. IND trials. It covers expedited reporting, narrative submissions, follow-up reports, database management, and inspection readiness.

Responsibilities

• Sponsor: Ensures compliance with FDA reporting timelines, submits expedited reports, and maintains safety databases.
• Investigator: Reports all SAEs immediately to the sponsor, provides follow-up data, and documents assessments.
• CRO: Supports safety monitoring, reconciliation, and reporting activities.
• Pharmacovigilance Team: Manages safety database, performs case assessments, and prepares regulatory reports.
• Regulatory Affairs: Submits safety reports to FDA via electronic gateway.
• QA: Audits safety reporting workflows and inspection readiness.

Accountability

The Sponsor’s Drug Safety Officer is accountable for IND safety reporting compliance. Investigators remain accountable for subject-level SAE reporting.

Procedure

1. SAE Identification
1.1 Investigators must report SAEs to sponsor within 24 hours of awareness.
1.2 Record in SAE Log (Annexure-1).

2. Sponsor Evaluation
2.1 Assess causality, expectedness, and seriousness of each SAE.
2.2 Record assessment in SAE Assessment Log (Annexure-2).

3. Expedited Reporting to FDA
3.1 Report fatal or life-threatening SUSARs within 7 calendar days.
3.2 Report other SUSARs within 15 calendar days.
3.3 Submit reports via FDA electronic gateway (MedWatch Form 3500A).
3.4 Document in Expedited Reporting Log (Annexure-3).

4. Follow-Up Reports
4.1 Submit additional data or narratives as follow-up within 15 days.
4.2 Record in Follow-Up Reporting Log (Annexure-4).

5. Annual IND Reports
5.1 Submit annual safety report (DSUR/IND Annual Report) summarizing all SAEs.
5.2 Record in Annual Safety Report Log (Annexure-5).

6. Safety Database Management
6.1 Maintain validated safety database with audit trails.
6.2 Perform reconciliation with clinical databases quarterly.
6.3 Record in Database Reconciliation Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain safety records in inspection-ready format.
7.2 Conduct mock inspections documented in Safety Inspection Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• IND: Investigational New Drug
• DSUR: Development Safety Update Report
• CRO: Contract Research Organization
• QA: Quality Assurance
• FDA: Food and Drug Administration
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. SAE Log (Annexure-1)
2. SAE Assessment Log (Annexure-2)
3. Expedited Reporting Log (Annexure-3)
4. Follow-Up Reporting Log (Annexure-4)
5. Annual Safety Report Log (Annexure-5)
6. Database Reconciliation Log (Annexure-6)
7. Safety Inspection Log (Annexure-7)

References

• 21 CFR 312.32 – IND Safety Reporting
• FDA – IND Safety Reporting Guidance
• ICH GCP – E2A and E2F Safety Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: SAE Log

Annexure-2: SAE Assessment Log

Annexure-3: Expedited Reporting Log

Annexure-4: Follow-Up Reporting Log

Annexure-5: Annual Safety Report Log

Annexure-6: Database Reconciliation Log

Annexure-7: Safety Inspection Log

Revision History

For more SOPs visit: Pharma SOP